BUSINESS/FINANCE NEWS
Setup News Ticker
   BUSINESS/FINANCE NEWS
Searching for 'COVID-19 vaccine'. (Return)

MarketWatch MarketPulseJan 25, 2021
Moderna: Lab study confirms its COVID-19 vaccine still protects against new variants
Shares of Moderna Inc. gained 4.6% in premarket trading on Monday afer the company said laboratory studies demonstrated that its COVID-19 vaccine can still protect people against two new coronavirus variants: the B.1.1.7 that was first identified in the United Kingdom, and the B.1.351 strain, out of South Africa. The study was not conducted in humans. The findings were released in a news release, and the company said it expects the results to be published in preprint form. Moderna said the in-vitro studies showed that the B.1.1.7 variant had no "significant" impact on neutralizing antibody titers developed as a result of vaccination; however, they also demonstrated that the vaccine was less effective against the B.1.351 variant. In this case, the vaccine still produced levels of neutralizing antibody titers that were protective, but the titer levels were lower. Moderna said it now plans to study booster doses for its two-dose COVID-19 vaccine, to see if a third dose of some kind can increase neutralizing antibody titers and if a booster can specifically protect against the B.1.351 variant. This booster, mRNA-1273.351, will be tested in preclinical studies and a Phase 1 study in the U.S. The U.K. and South Africa variants have caused concern from government officials and medical experts around the world because they are more infectious and carry a higher viral load than other strains of the virus. Moderna's stock has gained 520.3% over the past 12 months, while the S&P 500 is up 15.6%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.



RELATED ARTICLES
Merck Stops Developing Both Of Its COVID-19 Vaccine Candidates (NPR Topics: Business)

Chicago Tribune Business NewsJan 25, 2021
Merck giving up on two potential COVID-19 vaccines after poor test results
Merck is halting work on two potential COVID-19 vaccines following poor results in early-stage studies.The drugmaker said it will focus instead on studying two possible treatments for the virus that also have yet to be approved by regulators.

RELATED ARTICLES
Merck abandons bid to develop Covid-19 vaccine (FT.com - US)

MarketWatch MarketPulseJan 25, 2021
CDC: Moderna's COVID-19 vaccine can cause allergic reaction in some people
The Centers for Disease Control and Prevention said Friday that Moderna Inc.'s COVID-19 vaccine produces an allergic reaction in a small percentage of people, similar to the agency's findings about the coronavirus vaccine developed by BioNTech SE and Pfizer Inc. . Moderna's stock was up 1.6% in premarket trading on Monday. There were 10 cases of anaphylaxis among the roughly 4 million doses administered between Dec. 21 and Jan. 10, according to the CDC report. Both vaccines are mRNA-based vaccines, with similar efficacy rates in clinical trials. They are the only two COVID-19 vaccines that have been authorized in the U.S. so far during the pandemic. The CDC previously recommended that health care providers prepare for the possibility of anaphylaxis among some people who get vaccinated. Moderna's stock has soared 520.3% over the past 12 months, while the S&P 500 is up 15.6%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.



Google Business NewsJan 25, 2021
Coronavirus updates: 2 in 5 Americans live where hospitals are at capacity; Japan scrambling for 'herd immunity' ahead of Olympics - USA TODAY
Coronavirus updates: 2 in 5 Americans live where hospitals are at capacity; Japan scrambling for 'herd immunity' ahead of Olympics  USA TODAYMAP: Where to get the COVID-19 vaccine in Pennsylvania  The Morning CallSussex County COVID-19 January 24  TAPinto.netLetters to the Editor - Dallas-area residents share concerns and complaints about getting the COVID-19  The Dallas Morning News

MarketWatch MarketPulseJan 25, 2021
Merck to discontinue development of COVID-19 vaccines, focus on two investigational therapies
Merck said Monday it is discontinuing development of its two COVID-19 vaccine candidates following disappointing trial results, and will instead focus on the development of two investigational therapeutic candidates. The decision comes after a review of findings from Phase 1 studies of the vaccine candidates, named V590 and V591, in which immune responses were inferior to those seen following natural infection and in trials of other vaccine candidates. "Merck continues to advance clinical programs and to scale-up manufacturing for two investigational medicines, MK-7110 and MK-4482 (molnupiravir); molnupiravir is being developed in collaboration with Ridgeback Bio," the company said in a statement. The company is expecting to book a charge in the fourth quarter, but did not offer any further details. Merck is still planning to submit the results of the early-stage trial for publication in a peer-reviewed journal. Shares fell 1.2% premarket and are down 6% in the last 12 months, while the S&P 500 has gained 16.6%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.



Google Business NewsJan 24, 2021
More than two-thirds of Americans approve of Biden's coronavirus response: poll | TheHill - The Hill
More than two-thirds of Americans approve of Biden's coronavirus response: poll | TheHill  The HillBiden is planning a busy week of executive action. Here's what you need to know  CNNCDC director: "I cannot tell you how much vaccine we have"  Yahoo NewsBiden's Two challenges: Covid and Congress | Meet The Press | NBC News  NBC NewsWhite House begins talks with lawmakers on COVID-19 relief  The Associated Press
TRENDING TAGS
StockBuy Market Futures How Week
Bidentravel American reinstate ban Covid
CovidCOVID-19 Vaccine positive Biden Merck
COVID-19vaccine Positive Merck toll President
VaccineCOVID-19 Covid Merck Moderna how
BusinessHow Capital Insider Oil pandemic
Earningsweek Futures Apple Ahead Tesla
ChinaBillion IPO Evergrande Biden Love
capitalbusiness Shares Evergrande EV surge
StocksBuy these Goldman Sachs warns

NEWS SOURCES
Top News (Business News)
Accounting Today
AdWeek News
Banking Business Review
Barron's This Week Magazine
Barron's Up and Down Wall Street Daily
Brad Ideas
Chicago Tribune Business News
CNBC Business
CNBC Economy
CNBC Finance
CNN/Money
CNN/Money Real Estate News
Dismal.com: Analysis
Dismal.com: Indicators
Enterprise Application News
Entrepreneur.com
Forbes Headlines
Forbes Social Media News
FT.com - China, Economy & Trade
FT.com - Financial Markets
FT.com - Hedge Funds
FT.com - Telecoms
FT.com - US
Google Business News
Google Market News
HBS Working Knowledge
Inc.com
INSEAD Knowledge
International Tax Review
Kiplinger
Knowledge@Wharton
L.S. Starrett News
MarketWatch
MarketWatch Breaking News
MarketWatch MarketPulse
McKinsey Quarterly
MSNBC.com: Business
Nielsen Trends
NonProfit Times
NPR Topics: Business
NYTimes Business
OpinionJournal.com
Private Equity Breaking News
Reuters Business
Reuters Company News
Reuters Money
SEC.gov Updates: News Digest
SHRM HR News
Tax Policy News
The Economist International News
The Motley Fool
USA Today Money
Wall Street Journal US Business
Wall Street Transcript
Washington Post Business
WSJ Asia
WSJ Europe
WSJ MoneyBeat
WSJ Opinion
WSJ US News
WSJ World Markets
Yahoo Business
  • CEOExpress
  • 1 Boston Place | Suite 2600
    Boston MA 02108
  • Contact
  • As an Amazon Associate
    CEOExpress earns from
    qualifying purchases.

©1999-2021 CEOExpress Company LLC